CAMP4 Therapeutics Corporation Earnings Per Share (Basic)
CAMP4 Therapeutics Corporation (CAMP) reported Earnings Per Share (Basic) of -$0.58 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-13
- CAMP4 Therapeutics Corporation earnings per share, basic for the quarter ending 2026-06-30 was -$0.58.
- CAMP4 Therapeutics Corporation earnings per share, basic for the quarter ending 2026-03-31 was -$0.32.
- CAMP4 Therapeutics Corporation earnings per share, basic for the quarter ending 2025-12-31 was -$0.75.
- CAMP4 Therapeutics Corporation earnings per share, basic for the quarter ending 2025-09-30 was -$0.55.
- CAMP4 Therapeutics Corporation earnings per share, basic for fiscal 2025 was -$2.65.
- CAMP4 Therapeutics Corporation earnings per share, basic for fiscal 2024 was -$11.04.
- CAMP4 Therapeutics Corporation earnings per share, basic for fiscal 2023 was -$124.80.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$0.58 10-Q · filed 2026-08-13 | -$0.90 10-Q · filed 2026-08-13 | -$1.63 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$2.18 derived: net income ÷ weighted average shares · filed 2026-08-13 |
| 2026-03-31 | -$0.32 10-Q · filed 2026-05-07 | -$1.05 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$1.59 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$2.17 derived: net income ÷ weighted average shares · filed 2026-08-13 |
| 2025-12-31 | -$0.75 derived: net income ÷ weighted average shares · filed 2026-03-05 | -$1.37 derived: net income ÷ weighted average shares · filed 2026-03-05 | -$2.01 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$2.65 10-K · filed 2026-03-05 |
| 2025-09-30 | -$0.55 10-Q · filed 2025-11-06 | -$1.17 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$1.78 10-Q · filed 2025-11-06 | -$2.52 derived: net income ÷ weighted average shares · filed 2026-08-13 |
| 2025-06-30 | -$0.62 10-Q · filed 2026-08-13 | -$1.24 10-Q · filed 2026-08-13 | -$2.00 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$3.56 derived: net income ÷ weighted average shares · filed 2026-08-13 |
| 2025-03-31 | -$0.62 10-Q · filed 2026-05-07 | -$1.37 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$3.10 derived: net income ÷ weighted average shares · filed 2026-05-07 | |
| 2024-12-31 | -$0.77 derived: net income ÷ weighted average shares · filed 2026-03-05 | -$3.01 derived: net income ÷ weighted average shares · filed 2026-03-05 | -$11.04 10-K · filed 2026-03-05 | |
| 2024-09-30 | -$24.19 10-Q · filed 2025-11-06 | -$76.50 10-Q · filed 2025-11-06 | ||
| 2024-06-30 | -$26.00 10-Q · filed 2025-08-14 | -$52.56 10-Q · filed 2025-08-14 | ||
| 2024-03-31 | -$26.57 10-Q · filed 2025-05-13 | |||
| 2023-12-31 | -$124.80 10-K · filed 2025-03-27 | |||
| 2023-09-30 | -$29.21 10-Q · filed 2024-11-21 | -$94.62 10-Q · filed 2024-11-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |